AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026)
AtaiBeckley (ATAI) reported Net Income towards Common Stockholders of -$61.1 million for Q3 2025, down 132.34% on a YoY basis from $188.8 million in Q3 2024, and down 120.25% sequentially from -$27.7 million in Q2 2025.
AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
AtaiBeckley's Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 12.68% year-over-year to -$29.8 million in Q1 2026; TTM through Mar 2026 was -$56.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$659.9 million, down 344.64% from the prior year.
- Net Income towards Common Stockholders slipped to -$61.1 million in Q3 2025, from -$27.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$26.4 million in Q1 2025 and bottomed at -$29.8 million in Q1 2026.
- A 5-year average of -$30.3 million and a median of -$33.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders plunged 741.53% in 2022 and surged 230.56% in 2023, its largest moves.
- Tracing ATAI's Net Income towards Common Stockholders over 5 years: stood at -$49.3 million in 2021, then advanced by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then sank by 107.97% to -$39.0 million in 2024, then slumped by 56.64% to -$61.1 million in 2025.
- Business Quant data shows ATAI's Net Income towards Common Stockholders at -$61.1 million in Q3 2025, -$27.7 million in Q2 2025, and -$26.4 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - | -61.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.78 Mn |
| Sep 30, 2025 | -61.07 Mn |
| Jun 30, 2025 | -27.73 Mn |
| Mar 31, 2025 | -26.43 Mn |
| Mar 31, 2025 | -26.43 Mn |
| Dec 31, 2024 | -38.99 Mn |
| Sep 30, 2024 | -26.29 Mn |
| Jun 30, 2024 | -57.31 Mn |
| Mar 31, 2024 | -26.71 Mn |
| Dec 31, 2023 | -18.75 Mn |
| Sep 30, 2023 | 44.24 Mn |
| Jun 30, 2023 | -33.04 Mn |
| Mar 31, 2023 | -33.14 Mn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -33.89 Mn |
| Jun 30, 2022 | -36.62 Mn |
| Mar 31, 2022 | -36.87 Mn |
| Dec 31, 2021 | -49.30 Mn |
| Sep 30, 2021 | -31.16 Mn |
| Jun 30, 2021 | -48.46 Mn |